SCHEMBL21748741

SCHEMBL21748741

CC(C)(C)OC(=O)N1CC(N)C2(CC2)C1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.42
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM1A O60341 2/20 0.39
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
RORC P51449 3/20 0.38
HPGD P15428 1/20 0.38
EPHX2 P34913 1/20 0.38
RECQL P46063 1/20 0.36
EPHX1 P07099 1/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
THRB P10828 1/20 0.36
NAMPT P43490 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30595257 1.00 NR1H2 (0.42) NR1H2USP2SMN1; SMN2KDM1ADDB1
SCHEMBL24231705 1.00 NR1H2 (0.42) NR1H2USP2SMN1; SMN2KDM1ADDB1
SCHEMBL17107694 0.94 NR1H2 (0.40) NR1H2USP2SMN1; SMN2KDM1ADDB1
SCHEMBL16113298 0.94 NR1H2 (0.40) NR1H2USP2SMN1; SMN2KDM1ADDB1
SCHEMBL21748754 0.84 HPGD (0.46) USP2SMN1; SMN2KDM1AHPGDEPHX2
SCHEMBL25465739 0.84 HPGD (0.46) USP2SMN1; SMN2KDM1AHPGDEPHX2
SCHEMBL17499918 0.82 NR1H2 (0.43) NR1H2USP2SMN1; SMN2DDB1CRBN
SCHEMBL21597767 0.81 NR1H2 (0.42) NR1H2USP2SMN1; SMN2DDB1CRBN
SCHEMBL15719645 0.81 NR1H2 (0.42) NR1H2USP2SMN1; SMN2DDB1CRBN
SCHEMBL31722107 0.81 NR1H2 (0.42) NR1H2USP2SMN1; SMN2DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-13 US disclosed
CN-113950477-B Granulin precursor modulators and methods of use thereof 阿库达医疗公司 2024-07-05 CN disclosed
WO-2024145483-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME HTG MOLECULAR DIAGNOSTICS, INC. (US) 2024-07-04 WO disclosed
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-11 US disclosed
CN-116583502-A Bicyclic-heterocyclic derivatives and their use as orexin-2 receptor agonists 欧瑞夏治疗有限公司 2023-08-11 CN disclosed
US-20230021834-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-01-26 US disclosed
US-20220251084-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME JANSSEN PHARMACEUTICA NV (BE) 2022-08-11 US disclosed
EP-3983401-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Arkuda Therapeutics (US) 2022-04-20 EP disclosed
US-11045457-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-06-29 US disclosed
WO-2020252222-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2020-12-17 WO disclosed
WO-2020252222-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2020-12-17 WO disclosed
US-20200061041-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11045457-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates SSTR4, SSTR3, NPY4R NR1H2 1215/4885USP2 1986/4885SMN1; SMN2 933/4885
US-20220251084-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME GRN, PRNP, PSEN2 NR1H2 4250/4885USP2 2387/4885SMN1; SMN2 644/4885
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates SSTR4, SSTR3, NPY4R NR1H2 1215/4885USP2 1986/4885SMN1; SMN2 933/4885
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R NR1H2 1215/4885USP2 1986/4885SMN1; SMN2 933/4885
US-20200061041-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R NR1H2 1215/4885USP2 1986/4885SMN1; SMN2 933/4885
US-20230021834-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R NR1H2 1215/4885USP2 1986/4885SMN1; SMN2 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.